{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T10:09:24Z","timestamp":1783764564837,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,13]]},"DOI":"10.7759\/cureus.29130","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T18:36:34Z","timestamp":1663094194000},"source":"Crossref","is-referenced-by-count":2,"title":["Vasoactive Intestinal Peptide Tumor as the Cause of Persistent Diarrhea: A Diagnostic Challenge"],"prefix":"10.7759","author":[{"given":"Sara","family":"Lopes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315909","article-title":"Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition","volume":"67","author":"Arasaradnam RP","year":"2018","unstructured":"Arasaradnam RP, Brown S, Forbes A, et al.. Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition. Gut. 2018, 67:1380-99. 10.1136\/gutjnl-2017-315909","journal-title":"Gut"},{"key":"ref2","article-title":"Clinicopathological data and treatment modalities for pancreatic vipomas: a systematic review","volume":"24","author":"Schizas D","year":"2019","unstructured":"Schizas D, Mastoraki A, Bagias G, et al.. Clinicopathological data and treatment modalities for pancreatic vipomas: a systematic review. J BUON. 2019, 24:415-23.","journal-title":"J BUON"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000001347","article-title":"Diagnostic and management challenges in vasoactive intestinal peptide secreting tumors: a series of 15 patients","volume":"48","author":"Angelousi A","year":"2019","unstructured":"Angelousi A, Koffas A, Grozinsky-Glasberg S, et al.. Diagnostic and management challenges in vasoactive intestinal peptide secreting tumors: a series of 15 patients. Pancreas. 2019, 48:934-42. 10.1097\/MPA.0000000000001347","journal-title":"Pancreas"},{"key":"ref4","article-title":"Vasoactive Intestinal Peptide Tumor (VIPoma)","author":"Zandee WT","year":"2021","unstructured":"Zandee WT, Hofland J, de Herder WW. Vasoactive Intestinal Peptide Tumor (VIPoma). Endotext. Feingold KR, Anawalt B, Boyce A, et al. (ed): MDText.com, Inc., South Dartmouth, MA; 2021."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/s0950-3528(96)90018-4","article-title":"Vasoactive intestinal polypeptide-secreting tumours: biology and therapy","volume":"10","author":"Park SK","year":"1996","unstructured":"Park SK, O'Dorisio MS, O'Dorisio TM. Vasoactive intestinal polypeptide-secreting tumours: biology and therapy. Baillieres Clin Gastroenterol. 1996, 10:673-96. 10.1016\/s0950-3528(96)90018-4","journal-title":"Baillieres Clin Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1988.tb27006.x","article-title":"Somatostatin and analogues in the treatment of VIPoma","volume":"527","author":"O'Dorisio TM","year":"1988","unstructured":"O'Dorisio TM, Gaginella TS, Mekhjian HS, Rao B, O'Dorisio MS. Somatostatin and analogues in the treatment of VIPoma. Ann N Y Acad Sci. 1988, 527:528-35. 10.1111\/j.1749-6632.1988.tb27006.x","journal-title":"Ann N Y Acad Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1111","article-title":"Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms","volume":"17","author":"Wymenga AN","year":"1999","unstructured":"Wymenga AN, Eriksson B, Salmela PI, et al.. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol. 1999, 17:1111. 10.1200\/JCO.1999.17.4.1111","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2021.08.001","article-title":"Efficacy of treatments for VIPoma: a GTE multicentric series","volume":"21","author":"Brugel M","year":"2021","unstructured":"Brugel M, Walter T, Goichot B, et al.. Efficacy of treatments for VIPoma: a GTE multicentric series. Pancreatology. 2021, 21:1531-9. 10.1016\/j.pan.2021.08.001","journal-title":"Pancreatology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2014.00007","article-title":"Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives","volume":"5","author":"Baldelli R","year":"2014","unstructured":"Baldelli R, Barnabei A, Rizza L, et al.. Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives. Front Endocrinol (Lausanne). 2014, 5:7. 10.3389\/fendo.2014.00007","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e3181b2bc7c","article-title":"Diagnosis and treatment of pancreatic vasoactive intestinal peptide endocrine tumors","volume":"38","author":"Song S","year":"2009","unstructured":"Song S, Shi R, Li B, Liu Y. Diagnosis and treatment of pancreatic vasoactive intestinal peptide endocrine tumors. Pancreas. 2009, 38:811-4. 10.1097\/MPA.0b013e3181b2bc7c","journal-title":"Pancreas"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3109\/07435800.2010.525085","article-title":"Pancreatic neuroendocrine tumors","volume":"36","author":"Batcher E","year":"2011","unstructured":"Batcher E, Madaj P, Gianoukakis AG. Pancreatic neuroendocrine tumors. Endocr Res. 2011, 36:35-43. 10.3109\/07435800.2010.525085","journal-title":"Endocr Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/s0039-6109(05)70141-9","article-title":"Islet cell tumors of the pancreas: the medical oncologist's perspective","volume":"81","author":"Brentjens R","year":"2001","unstructured":"Brentjens R, Saltz L. Islet cell tumors of the pancreas: the medical oncologist's perspective. Surg Clin North Am. 2001, 81:527-42. 10.1016\/s0039-6109(05)70141-9","journal-title":"Surg Clin North Am"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.12968\/hosp.2000.61.12.1479","article-title":"Islet cell tumours: surgical treatment","volume":"61","author":"Aldridge MC","year":"2000","unstructured":"Aldridge MC. Islet cell tumours: surgical treatment. Hosp Med. 2000, 61:830-3. 10.12968\/hosp.2000.61.12.1479","journal-title":"Hosp Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0682","article-title":"Sunitinib achieved fast and sustained control of VIPoma symptoms","volume":"172","author":"de Mestier L","year":"2015","unstructured":"de Mestier L, Walter T, Brixi H, Lombard-Bohas C, Cadiot G. Sunitinib achieved fast and sustained control of VIPoma symptoms. Eur J Endocrinol. 2015, 172:K1-3. 10.1530\/EJE-14-0682","journal-title":"Eur J Endocrinol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v16.i24.2963","article-title":"Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors","volume":"16","author":"Strosberg J","year":"2010","unstructured":"Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol. 2010, 16:2963-70. 10.3748\/wjg.v16.i24.2963","journal-title":"World J Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(85)80153-0","article-title":"Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases","volume":"88","author":"Kraenzlin ME","year":"1985","unstructured":"Kraenzlin ME, Ch'ng JL, Wood SM, Carr DH, Bloom SR. Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology. 1985, 88:185-7. 10.1016\/s0016-5085(85)80153-0","journal-title":"Gastroenterology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(85)92235-4","article-title":"Regression of metastatic vipoma with somatostatin analogue SMS 201-995","volume":"1","author":"Clements D","year":"1985","unstructured":"Clements D, Elias E. Regression of metastatic vipoma with somatostatin analogue SMS 201-995. Lancet. 1985, 1:874-5. 10.1016\/s0140-6736(85)92235-4","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.2015.002980","article-title":"Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs","volume":"3","author":"Singh S","year":"2017","unstructured":"Singh S, Granberg D, Wolin E, et al.. Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs. J Glob Oncol. 2017, 3:43-53. 10.1200\/JGO.2015.002980","journal-title":"J Glob Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14051119","article-title":"Update on epidemiology, diagnosis, and biomarkers in gastroenteropancreatic neuroendocrine neoplasms","volume":"14","author":"Takayanagi D","year":"2022","unstructured":"Takayanagi D, Cho H, Machida E, et al.. Update on epidemiology, diagnosis, and biomarkers in gastroenteropancreatic neuroendocrine neoplasms. Cancers (Basel). 2022, 14:1119. 10.3390\/cancers14051119","journal-title":"Cancers (Basel)"},{"key":"ref20","article-title":"Detection of pancreatic neuroendocrine tumors (PNET) using semi-quantitative [68Ga]DOTATOC PET in combination with multiphase contrast-enhanced CT","volume":"58","author":"Froeling V","year":"2014","unstructured":"Froeling V, R\u00f6ttgen R, Collettini F, Rothe J, Hamm B, Brenner W, Schreiter N. Detection of pancreatic neuroendocrine tumors (PNET) using semi-quantitative [68Ga]DOTATOC PET in combination with multiphase contrast-enhanced CT. Q J Nucl Med Mol Imaging. 2014, 58:310-8.","journal-title":"Q J Nucl Med Mol Imaging"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/110892-vasoactive-intestinal-peptide-tumor-as-the-cause-of-persistent-diarrhea-a-diagnostic-challenge","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:47:33Z","timestamp":1707508053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/110892-vasoactive-intestinal-peptide-tumor-as-the-cause-of-persistent-diarrhea-a-diagnostic-challenge"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.29130","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,13]]}}}